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Abstract 
Background: Non-invasive monitoring of liver disease remains an important health issue. Liver secreted glycopro-
teins reflect pathophysiological states of the organ and represent a rational target for serologic monitoring. In this 
study, we describe sialylated O-glycoforms of liver-secreted hemopexin (HPX) and quantify them as a ratio of disi-
alylated to monosialylated form (S-HPX).
Methods: We measured S-HPX in serum of participants of the HALT-C trial using a LC–MS/MS-MRM assay.
Results: Repeated measurements of S-HPX in the samples of 23 disease-free controls, collected at four different time 
points, show that the ratio remains stable in the healthy controls but increases with the progression of liver disease. 
The results of measurement of S-HPX in serum of participants of the HALT-C trial show that it increased significantly 
(Kruskal–Wallis test, p < 0.01) in liver disease as the stage of fibrosis progressed in liver biopsies. We observed a 1.7-fold 
increase in fibrosis defined as Ishak score 3–4 (24.9 + 14.2, n = 22) and 4.7-fold increase in cirrhosis defined as Ishak 
score 5–6 (68.6 + 38.5; n = 24) compared to disease-free controls (14.7 + 6.7, n = 23). S-HPX is correlated with AFP, 
bilirubin, INR, ALT, and AST while inversely correlated with platelet count and albumin. In an independent verification 
set of samples, S-HPX separated the Ishak 5–6 (n = 15) from the Ishak 3–4 (n = 15) participants with AuROC 0.84; at 
the same time, the Ishak 3–4 group was separated from disease-free controls (n = 15) with AuROC 0.82.
Conclusion: S-HPX, a measure of sialylated O-glycoforms of hemopexin, progressively increases in fibrotic and cir-
rhotic patient of HCV etiology and can be quantified by an LC–MS/MS-MRM assay in unfractionated serum of patients. 
Quantification of sialylated O-glycoforms of this liver secreted glycoprotein represents a novel measure of the stage of 
liver disease that could have a role in monitoring the progression of liver pathology.
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Background
Hepatitis C virus (HCV) is a leading cause of chronic 
liver disease in the US [1, 2]. Approximately 20  % of 
chronic HCV cases develop liver cirrhosis and 2.5  % 
develop HCC which appears most commonly in cirrhotic 
livers [3]. While the recently available HCV treatment 
regimens are expected to eventually decrease the burden 
of liver disease [4], the large number of unidentified and 
untreated HCV infections, uncertain reversibility of liver 
damage, and increasing impact of NAFLD/NASH suggest 
that non-invasive monitoring of liver disease remains an 
important clinical issue [3, 5, 6].
Biopsy is the diagnostic standard for monitoring of liver 
disease in spite of its invasive nature, associated compli-
cations, and inconsistent sampling [7]. It is expected that 
non-invasive detection of liver fibrosis at a potentially 
reversible stage, improved predictive models of liver dis-
ease progression, and detection of resectable early stage 
HCC will have major impact on disease outcomes [8, 9]. 
This has stimulated considerable interest in non-invasive 
serologic, liver function, and imaging tests that could 
complement biopsy in liver disease classification [10, 11]. 
In spite of these efforts, alternatives to biopsy have not 
yet reached general acceptance and the search for viable 
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options continues. We have therefore designed new sero-
logic assays for monitoring of unusual glycoforms of liver 
secreted proteins [12, 13] and evaluated, for the first time, 
the potential of sialylated O-glycoforms of hemopexin 
(HPX) in serologic monitoring of liver disease.
Glycosylation is a common and diverse modification of 
proteins secreted by the liver. Two major pathways of gly-
cosylation of secretory proteins have been described: (1) 
N-glycosylation of asparagine (Asn) in the sequence Asn-
X-Ser/Thr (X ≠ Pro); and (2) mucin-type O-glycosylation 
of serine or threonine (Ser/Thr) without a well-defined 
sequence motif. Diversity and functions of the proteome 
are substantially expanded by these modifications [14, 
15]. We and others have shown that changes in protein 
glycosylation accompany the development of fibrosis, 
cirrhosis, and HCC [16–19]. Unusual N-glycoforms of 
immunoglobulins as well as liver secreted proteins have 
been proposed as serologic tests for the monitoring of 
liver disease [16, 20, 21]. Methodological improvements 
show that O-glycosylation of proteins is as common and 
important as N-glycosylation [22]; however, O-glycosyla-
tion of liver secreted proteins remains largely unused in 
serologic assays of liver disease. We have therefore exam-
ined a common type of O-glycosylation, the GalNAc α 
Ser/Thr linkage, known as mucin type O-glycosylation 
[23]. We do this because mucin type O-glycans have pro-
found functional impact [24, 25] and are associated with 
a wide range of proteins, including liver secreted glyco-
proteins which can be followed by serologic assays [26–
28]. The truncated O-glycans of Tn and STn antigens, 
one of the well-known examples of disease-associated 
O-glycoforms [29], affect gastrointestinal (patho)physiol-
ogy and are increased in tumors [30, 31]. However, the 
structural and functional variants of mucin type O-gly-
coforms associated with specific proteins and disease 
processes only begin to be understood [5, 32]. We have 
therefore selected HPX as a model liver secreted glyco-
protein to study changes in the detectable site-specific 
O-glycoforms in liver disease.
HPX is secreted mainly by hepatocytes, binds heme in 
the blood stream, and the complex is cleared from cir-
culation by a hepatocyte-specific membrane receptor 
[33]. It was reported that serum concentration of HPX 
[0.4–1.5  g/L] does not vary significantly in liver disease 
[15]. While N-glycosylation of HPX is altered in liver 
disease [21, 34, 35], O-glycosylation of HPX was not to 
our knowledge examined in this context. Wada et  al. 
[26] documented that at least three O-glycosylation sites 
at the N-terminus of HPX carry O-glycans and that the 
N-terminal threonine of human HPX is consistently and 
fully occupied by the mucin type O-glycans. Because 
of low variability of this O-glycosylation of HPX, the 
authors proposed that it could serve as a new marker of 
congenital disorders of glycosylation [26]. We therefore 
examine O-glycoforms of HPX at progressing stages of 
liver disease of HCV etiology. To this end, we have devel-
oped targeted LC–MS/MS-MRM methods for quanti-
fication of the site-specific O-glycoforms of HPX and 
applied them to the study of HPX samples of participants 




The initial discovery of O-glycoforms of HPX associated 
with liver disease progression was carried out using sam-
ples of HCC patients (n = 10), cirrhotic patients (n = 10), 
and healthy individuals (n = 10) enrolled in collaboration 
with the Department of Hepatology and Liver Transplan-
tation, Georgetown University Hospital, Washington, DC 
under protocols approved by the Institutional Review 
Board as described previously [36]. Briefly, all patients 
(HCC and cirrhosis) selected for this study had chronic 
HCV infection as primary diagnosis and all the HCC 
participants had stage 1 and 2 tumors according to the 
7th edition of the American Joint Committee on Can-
cer Staging manual. Blood samples were collected using 
EDTA Vacutainer tubes (BD Diagnostics, Franklin Lakes, 
NJ, USA); plasma was collected according to the manu-
facturer’s protocol and was stored at −80  °C until use. 
Participants were split into groups of five and plasma was 
pooled for analysis (two pools per group, five participants 
per pool). All the groups were matched on age, race (60 % 
Caucasian, 40  % African-American), and gender (80  % 
males); HCC and cirrhosis groups were further matched 
on MELD score as described in the previous literature 
[36].
Further serum samples were provided by NIDDK from 
the HALT-C trial, a prospective randomized controlled 
trial of 1050 patients that evaluated effect of long-term 
low-dose peginterferon alpha-2a in participants that 
failed initial anti-HCV therapy with interferon [37, 38]. 
A total of 114 participants (76 liver disease patients from 
the HALT-C trial and 38 disease-free controls recruited 
at Georgetown University) (35) were included in the anal-
ysis (Table  1). Liver disease status of the HALT-C par-
ticipants was classified based on biopsy-evaluation into 
fibrosis (Ishak score 3–4, n = 37) or cirrhosis (Ishak score 
5–6, n = 39) groups. To minimize classification error, we 
selected patients with consistent Ishak scores at three 
biopsy measurements at month 0, 24, and 48 after rand-
omization. However, two fibrotic participants with Ishak 
3 had only one biopsy and seven participants (three cir-
rhotic and four fibrotic) crossed disease categories at one 
biopsy time point. For those participants, we analyzed 
blood samples collected at a time point closest to the 
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disease outcome consistent with their group assignment. 
The two groups of liver disease participants and the con-
trols were matched on age and gender. The disease-free 
participants donated blood samples at four successive 
visits in the span of 1 year and answered a brief question-
naire inquiring about basic demographic information and 
medical history. The study groups were further divided 
into discovery (23 disease-free controls, 22 fibrosis, and 
24 cirrhotic) and verification (15 disease-free controls, 15 
fibrotic, and 15 cirrhotic) sets of participants (Additional 
file 1). The fibrosis and cirrhosis groups in the discovery 
sets consist of similar proportions of participants from 
the IFN treatment and control arms of the HALT-C trial; 
the verification set consist of participants from the con-
trol arm.
Isolation of HPX and separation of glycopeptides by HILIC 
chromatography
HPX was purified from plasma by hemin affinity followed 
by C18 chromatography as described previously [12]. 
Isolated HPX (20 pmol), dried in a vacuum concentrator 
and stored at −80 °C, was suspended in 50 mM ammo-
nium bicarbonate solution, pH 7.8 (Sigma-Aldrich, St. 
Louis, MO, USA) with 0.05  % RapiGest (Waters, Mil-
ford, MA, USA), reduced, alkylated, and digested with 
0.2 µg of Trypsin Gold for MS (Promega, Madison, WI, 
usa) in a Barocycler reactor (Pressure BioSciences, South 
Easton, MA, USA) at 37 °C for 60 min as described [12]. 
O-glycopeptides were isolated by HILIC chromatography 
on a ZIC-HILIC column 150 ×  2.1  mm, 3  μm particles 
(EMD Merck, Germany) in a 30  min HPLC (Agilent, 
Santa Clara, CA, USA) gradient of ACN/H2O with 0.01 % 
TFA. Starting conditions were set to 90  % ACN with 
0.01 % TFA followed by 30 min gradient elution to 90 % 
of H2O with 0.01 % TFA. Peptides were monitored at 214 
and 280 nm using a DAD detector (Agilent Technologies, 
Santa Clara, CA, USA). Glycopeptide fractions were col-
lected and dried on a vacuum concentrator (Labconco, 
Kansas City, MO, USA) for further use.
De‑sialylation and exoglycosidase treatment of the 
O‑glycopeptides of HPX
Tryptic digest of HPX or the HILIC-enriched glycopep-
tide fractions of the tryptic digest were de-sialylated with 
2  M acetic acid (Sigma-Aldrich) at 80  °C for 2  h. Com-
pletion of the de-sialylation reaction was confirmed by 
LC–MS/MS analysis (Additional file  1). De-sialylated 
glycopeptides were evaporated in a vacuum concentra-
tor (Labconco) and further treated with 0.1 U of 1–3 beta 
galactosidase (New England BioLabs, Ipswich, MA, USA) 
in 50 mM sodium acetate, pH 6, at 37 °C for 8 h. Products 
of the reaction were cleaned for further analysis by SPE 
C18, concentrated using vacuum concentrator, and dis-
solved in 0.1 % formic acid for further LC–MS analysis.
LC–MS/MS analysis
Tryptic digest of HPX, HILIC-enriched fractions, or 
acid- and exoglycosidase-treated glycopeptide fractions 
were analyzed under identical chromatographic condi-
tions. Peptides were separated by reversed phase chro-
matography (Tempo Eksigent-AB Sciex, Framingham, 
MA, USA) on a ChromXP C18-CL (3 μm, 120Å, 180 μm, 
20 mm) trap column and ChromXP C18-CL (3 μm, 120 
Å, 75  μm, 150  mm) HPLC capillary chip column (Eksi-
gent-AB Sciex) interfaced with a 5600 TripleTOF mass 
spectrometer (AB Sciex, Framingham, MA, USA). Chro-
matographic method consisted of 10-min trapping/wash-
ing step [2 % ACN, 0.1 % formic acid (FA)] at 3 μL/min 
flow rate and 30  min gradient elution at a flow rate of 
300 nL/min (solvent A: 2 % ACN with 0.1 % FA; solvent 
B: 100 % ACN with 0.1 % FA) using the following time-
table: 5–45  % solvent B 0–23  min; 45–100  % solvent B 
23–25 min; 100 % solvent B 25–30 min. Mass spectrom-
eter was set to ion spray voltage 2400 V, ion source gas 
(GS1) 13, declustering potential 90 and interface heater 
temperature 150  °C, and operated in data-dependent 
mode; each survey scan (m/z 400–1600) was followed by 
MS/MS on 25 precursor ions in the range m/z 100–1800, 
Table 1 Basic characteristics of  disease-free controls 
and groups of the HALT-C participant
Values are expressed as mean ± SD
a p value was calculated using Mann–Whitney U test or Kruskal–Wallis test for 
quantitative variables and Chi square test for categorical variables
b Six healthy controls belong to the Hispanic ethnic group
Healthy Fibrosis Cirrhosis p valuea
N 38 37 39 n/a
Male (%) 68 59 72 0.502
Race (CA/AA) 20/12b 30/7 28/11 0.106
Age 49.3 ± 7.7 50.1 ± 7.1 50.9 ± 6.5 0.614
IFN treatment  
(yes/no)
n/a 13/24 12/27 0.686
ALT (U/L) n/a 89.1 ± 41.3 129.7 ± 69.5 0.007
AST (U/L) n/a 67.4 ± 25.6 110.0 ± 65.0 0.002
Platelet (109/L) n/a 191.2 ± 59.4 144.7 ± 57.4 <0.001
Albumin (g/dL) n/a 4.0 ± 0.3 3.8 ± 0.4 0.115
AFP (ng/mL) n/a 11.7 ± 14.7 22.9 ± 24.6 0.005
Alkaline phos-
phatase (U/L)
n/a 91.7 ± 29.6 123.6 ± 52.1 0.636
INR n/a 1.0 ± 0.1 1.1 ± 0.1 <0.001
Bilirubin (mg/dL) n/a 0.7 ± 0.4 0.9 ± 0.4 0.039
Creatinine (mg/dL) n/a 0.8 ± 0.1 0.9 ± 0.2 0.936
MELD n/a 6.8 ± 1.3 7.5 ± 1.4 0.006
APRI n/a 0.9 ± 0.5 2.4 ± 2.5 <0.001
FIB-4 n/a 2.1 ± 1.1 3.5 ± 2.7 <0.001
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with the dynamic exclusion time set to 6  s, and 150 
counts threshold for two repeated precursors. Collision 
energy was set automatically according to charge state 
and m/z of precursor ion. Data depended analysis was 
used to identify major glycoforms and precursor XIC 
of 0.05 Da window was used to evaluate changes in gly-
coform quantities in liver disease (cirrhosis and HCC). 
Glycopeptide intensities were normalized to an internal 
tryptic peptide of HPX to eliminate influence of changes 
in the concentration of HPX protein on the quantitative 
outcome.
LC/MS3 and LC–MS/MS‑MRM analysis of the 
O‑glycopeptides of HPX
Studies of S-HPX in serum of patients were done directly 
without enrichment of HPX. Serum samples (2 µL) were 
diluted in 140 µL of 25 mM NH4HCO3 with 0.1 % Rapi-
Gest (Waters), reduced by 5  mM DTT for 1  h at 60  °C, 
and alkylated with 15 mM IAA for 20 min at room tem-
perature in the dark. Residual IAA was reduced with 
5  mM DTT for 20  min at RT. Reduced and alkylated 
samples (20 μL) were digested with trypsin in a Barocy-
cler reactor as described above. Tryptic peptides were 
analyzed on a NanoAcquity UPLC (Waters) by RP chro-
matography on a symmetry C18 (3 µm, 180 µm, 20 mm) 
trap column and UPLC capillary column (BEH 300Å, 
1.7  µm, 150  mm ×  0.75  µm) (Waters) interfaced with a 
6500 QTRAP mass analyzer (AB Sciex). Separation was 
achieved by a 60  min gradient elution with ACN con-
taining 0.1 % formic acid (B) starting from 2 % ACN with 
0.1 % formic acid (A) (0–1 min 99 % A, 1–20 min 99–50 % 
A, 20–38 min 50–2 % A, 38–45 min 2 % A, 45–45.5 min 
2–99 % A, 45.5–60 min 99 % (A). Ion source parameters 
were set to declustering potential 80 V, curtain gas 20, ion 
spray voltage 2400 V, ion source gas1 22, interface heater 
180  °C, entrance potential 10  V, collision exit potential 
13 V. We compared directly the MS/MS-MRM monitor-
ing to MS3 monitoring. The MS/MS-MRM measured the 
ratio of two analytes, the monoisalo-T glycopeptide to 
Y0 fragment transition (843.9 → 905.6) and the disialo-T 
glycopeptide to Y0 transition (916.7 → 905.6). The LOQ 
(S/N >10) of the monoisalo-T glycopeptide to Y0 frag-
ment transition is 5  fmol on column based on the addi-
tion of a stable isotope labeled glycopeptide standard. 
We could not determine absolute value of LOQ for the 
disialo-T glycopeptide because the synthetic standard is 
not available. However, the S/N of the transition was >10 
for all the samples examined. All parallel measurements of 
S-HPX were below 20 % RSD. The MS3 assay monitored 
THREE product ions (m/z: 504.1, 716.3 and 802.5) in the 
ion trap MS3 spectra with window width 3 Da; these three 
peptide backbone fragments derive from the peptide ion 
obtained in MS2 of the respective glycopeptide precursor 
ions as described (12). IT scan time of 2000 Da/s, Q0 trap-
ping and 20 ms fixed LIT fill time were used for the MS3 
method. A QC sample (one control serum sample) was 
prepared as described above and injected once per two 
sample injections in order to evaluate method stability 
and reproducibility. Data analysis was carried out using 
MultiQuant software 2.1 (AB Sciex).
Statistical analysis
The ratio of disialylated (NeuAc2Hex1HexNAc1) to mon-
osialylated (NeuAc1Hex1HexNAc1) glycoforms of the 
peptide TPLPPTSAHGNVAEGETKPDPVTER of HPX 
carrying one O-glycan on the T1 (S-HPX) was used as 
a final quantitative measure for evaluation of liver dis-
ease. S-HPX in the disease-free controls (n  =  38) was 
compared to the fibrosis (n = 37) and cirrhosis (n = 39) 
groups of participants in the HALT-C trial divided into 
and verification sample sets. All samples were blinded to 
the analyst and randomized in order of analysis. Descrip-
tive statistics of participants within the three disease 
groups are summarized in Table 1; Chi square tests were 
used for categorical variables and Mann–Whitney U test 
or Kruskal–Wallis test were for quantitative variables. 
S-HPX between the three disease groups in the discovery 
set (Fig. 3a), S-HPX between four different blood draws 
in the disease-free controls (Fig. 3b), and influence of IFN 
treatment on S-HPX (Additional file  1) were analyzed 
using Mann–Whitney U test or Kruskal–Wallis due to 
non-normality of S-HPX values. Logistic regression mod-
els were used to evaluate the association between S-HPX 
and liver disease status in the discovery set. Disease sta-
tus was the dependent variable and S-HPX was the main 
independent variable; other clinical variables including 
AFP and platelet count were used as independent vari-
ables. Model estimates can be found in Additional file 1. 
Optimal cut-off point for each independent variable was 
determined by maximizing sensitivity and specificity. The 
performance of S-HPX and other variables in classifica-
tion of liver disease was assessed using area under the 
receiver operating characteristic curve (AuROC) analysis 
in the verification set (Table  4) using the cut-off points 
derived from the discovery set. All reported p values are 
two sided. Statistical analyses were performed using SAS 
v 9.4 (SAS Institute, Cary, NC, USA).
Results
O‑glycopeptides of HPX in liver disease
Plasma samples from disease-free controls and cirrhotic 
patients (CIR) with or without HCC provided a base-
line for our examination of O-glycoforms of HPX detect-
able in liver disease. HPX was isolated by hemin affinity 
and C18 HPLC from the pooled plasma of participant 
as described in “Patients, materials and methods”. The 
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yield of HPX, purified to >95 % purity, was 20–25 µg per 
100 µL of plasma. Glycopeptides of HPX were enriched by 
HILIC chromatography (Fig. 1) and analyzed by LC–MS/
MS as described in [12, 19]. Combined analysis of all the 
pools led to the identification of 15 O-glycopeptides of 
HPX (Table  2) derived from the N-terminal tryptic pep-
tide of HPX, TPLPPTSAHGNVAEGETKPDPVTER. We 
did not observe other O-glycosylated peptides of HPX in 
any of the samples. Estimates of the abundance of these 
O-glycoforms, based on intensities of precursor ions 
in the LC–MS/MS scans, showed that two glycoforms 
(HexNAc-Gal-Neu5Ac, 66 % total intensity and HexNAc-
Gal-2Neu5Ac, 20 % total intensity) dominated the distribu-
tion. These two glycoforms were also clearly visible in the 
HILIC chromatograms by UV–Vis detection (Fig.  1). The 
chromatogram showed that the doubly sialylated glycoform 
(HexNAc-Gal-2Neu5Ac) increases in cirrhosis and HCC 
samples (red and green trace) compared to disease-free 
controls (blue trace) while the mono-sialylated O-glyco-
form (HexNAc-Gal-Neu5Ac) decreases. Major contribu-
tion of the above glycoforms to these isolated peaks was 
confirmed by LC–MS/MS analysis. Further analysis of the 
precursor ion peak-intensities in XIC of the LC–MS data 
confirmed the trend towards increased sialylation of the 
O-glycoforms of HPX in liver disease (Fig. 2). The results 
show an approximately fourfold increase in disialylated 
O-glycopeptide of HPX in cirrhosis and further increase 
in the cirrhotics with HCC with a simultaneous approxi-
mately 20 % decrease in the monosialylated O-glycopeptide 
of HPX. The changes are quite consistent in measurements 
of two independent pools of samples per group. Figure  2 
also shows that the minor O-glycoforms (2HexNAc-2Gal-
2Neu5Ac and 2HexNAc-2Gal-3Neu5Ac), which are 
about ten-times less intense, show a similar trend towards 
increased sialylation in the liver disease context.
We carried out LC-ETD/MS analysis of the enriched 
glycopeptides to understand whether the minor glyco-
forms represent large O-glycans attached to a single site 
or smaller O-glycans attached to several serines or thre-
onines in the peptide sequence. This technique allows 
fragmentation of the peptide backbone with preserva-
tion of the peptide-glycan bond which allows determina-
tion of sites occupied by the O-glycans [28]. To further 
increase efficiency of our analysis, we labeled the glyco-
peptides with mTRAQ reagent which increased charge 
state of the labeled peptides to (4+) and improved ETD 
fragmentation compared to the unlabeled glycopeptide 
in charge state (3+). Our analysis was further optimized 
Fig. 1 Peaks of the O-glycopeptides of HPX separated by HILIC chromatography. Peaks correspond to a tryptic digest of hemopexin (HPX) isolated 
from the plasma of controls (blue), cirrhotic (red) and HCC (green) patients. The peaks indicated by arrows represent the mono-sialylated core 1 
O-glycopeptide (RT 15.9 min, m/z 843.6) followed by the di-sialylated core 1 O-glycopeptide (RT 16.4 min, m/z 916.4)
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by removal of sialic acids from the microheterogeneous 
peptide population by treatment with acetic acid [26] 
which improved recovery of the informative fragments 
(Additional file 1). The analysis confirms that we observe 
smaller O-glycans on multiple serines/threonines. We 
observe glycosylation on serine or threonine other than 
T1 only when T1 is occupied which shows that O-glyco-
sylation of this peptide starts from the N-terminus and 
progresses to additional sites in the C-terminal direc-
tion. The additional sites are modified to a lesser degree 
than the T1 site. Fragmentation of the peptide shown in 
Additional file 1 documents that position T1 and T6 are 
occupied in case of doubly glycosylated peptide; triply 
glycosylated peptide is occupied at position T1, T6, and 
S7. This was further suggested by the lack of larger gly-
cans in the analysis of permethylated O-glycans detached 
by beta elimination (data not shown).
Analysis of S‑HPX in serum samples of the HALT‑C trial 
participants
Mono- and di- sialylated core-1 mucin type O-glycans 
attached to the T1 position of the N-terminal tryptic 
Table 2 Detected glycan compositions of the TPLPPTSAH-
GNVAEGETKPDPVTER O-glycopeptides in  tryptic digest 
of hemopexin isolated from pooled plasma of disease-free 
controls, cirrhotic, and HCC patients
Relative abundance is estimated as percent XIC signal of each glycopeptide 
(m/z) normalized to the sum of all O-glycopeptides
m/z Delta (ppm) Glycan composition XIC (%)
973.5 (3+) 9.55 HexNAc 0.35
770.9 (4+) 2.08 HexNAc-Gal 1.74
843.6 (4+) 3.20 HexNAc-Gal-Neu5Ac 66.19
916.4 (4+) 3.38 HexNAc-Gal-2Neu5Ac 19.61
894.4 (4+) −0.67 2HexNAc-Gal-Neu5Ac 0.16
934.9 (4+) 3.85 2HexNAc-2Gal-Neu5Ac 0.38
1007.7 (4+) 3.27 2HexNAc-2Gal-2Neu5Ac 7.22
1080.5 (4+) 4.54 2HexNAc-2Gal-3Neu5Ac 1.62
1153.2 (4+) 5.81 2HexNAc-2Gal-4Neu5Ac 0.68
1058.5 (4+) −5.29 3HexNAc-2Gal-2Neu5Ac 0.09
1099.0 (4+) 6.10 3HexNAc-3Gal-2Neu5Ac 0.15
937.6 (5+) 3.73 3HexNAc-3Gal-3Neu5Ac 1.23
995.8 (5+) 0.40 3HexNAc-3Gal-4Neu5Ac 0.45
1054.0 (5+) 1.99 3HexNAc-3Gal-5Neu5Ac 0.08
1112.3 (5+) 11.60 3HexNAc-3Gal-6Neu5Ac 0.04
Fig. 2 Quantification of the mono- and bis- sialylated O-glycopeptides of HPX. Quantification of mono- (HexNAc-Hex-Neu5Ac and 2HexNAc-2Hex-
2Neu5Ac) and bis- (HexNAc-Hex-2Neu5Ac and 2HexNAc-2Hex-3Neu5Ac) sialylated O-glycopeptides of HPX isolated from pooled plasma of healthy 
volunteers (white bars), cirrhotic (grey bars), and HCC (black bars) patients. Intensities of the peptides, doubly O-glycosylated at T1 and T6 (right side 
of the figure), are ×10 magnified. Results represent XIC of precursor ions normalized to an internal peptide of HPX and error bars represent analysis 
of two different plasma pools (samples of five participants in each pool) as described in “Patients, materials and methods” section
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peptide of HPX were the dominant liver secreted glyco-
forms (Table  2). These two glycoforms change substan-
tially in liver disease (Fig.  1) with several-fold increase 
in the disialylated O-glycoform of HPX and simultane-
ous approximately 20  % decrease in the monosialylated 
O-glycoform of HPX (Fig. 2). We have therefore selected 
ratio of the two major glycoforms, which we call S-HPX, 
as a quantitative measure for assessment of liver disease 
by our targeted LC/MS3 or LC–MS/MS-MRM assays 
[12]. Quantification of S-HPX was applied to serum sam-
ples of participants in the HALT-C trial (n = 76) and to 
disease-free controls (n  =  38). As expected, the clini-
cal variables including ALT, AST, bilirubin, INR, albu-
min, AFP, and platelet count significantly differ between 
the fibrosis and cirrhosis groups (Table 1). Likewise, the 
calculated MELD score, APRI and FIB-4 indexes signifi-
cantly differ between these two groups. The participants 
were further divided into discovery (23 disease-free con-
trols, 22 fibrosis, 24 cirrhosis) and verification (n  =  15 
each of the three groups) sets of samples (Additional 
file 1).
Quantification of S-HPX in the discovery set shows a 
significant increase in the fibrotic HALT-C participants 
compared to disease-free controls and further increase in 
the cirrhotic patients (Mann–Whitney U test, p < 0.001) 
(Fig. 3a). At the same time, analysis of S-HPX in disease-
free controls (n = 23) that provided samples at four dif-
ferent times in the span of a year showed consistently low 
S-HPX without significant differences between the draw 
times (Fig.  3b). Summary statistics of the S-HPX quan-
tification in both the discovery and the verification sets 
of samples are provided in Additional file 1. We did not 
observe significant influence of age, gender or race on 
S-HPX in any of the groups (Additional file 1). To evalu-
ate influence of IFN treatment on S-HPX, we selected a 
similar proportion of participants in the IFN treatment 
and control arms of the HALT-C trial in the discovery 
set. Our analysis shows a trend to lower S-HPX in the 
IFN treatment arm in both the fibrotic and cirrhotic 
groups but the changes do not reach significance (Addi-
tional file  1). Since the low dose interferon treatment is 
not clinically used we included only patients from the 
control arm of the HALT-C trial in the verification set.
Correlation analyses of clinical and demographic varia-
bles with S-HPX in the discovery set show multiple signif-
icant associations of weak to moderate strength (Table 3). 
S-HPX is correlated with AFP (rs = 0.58; p < 0.001), bili-
rubin (rs = 0.41; p = 0.008), INR (rs = 0.39; p = 0.012), 
ALT (rs = 0.34; p = 0.031), and AST (rs = 0.52; p = 0.001) 
while inversely correlated with platelet count (rs = −0.56; 
p  <  0.001) and albumin (rs  =  −0.44; p  =  0.004). This 
means that S-HPX is also positively correlated with the 
FIB-4 (rs = 0.61; p < 0.001) and APRI (rs = 0.56; p < 0.001) 
indexes based on combinations of the above variables. 
These associations are significant to a greater degree in 
the cirrhotic patients (Table 3). Scatter plots of the vari-
ables significantly associated with S-HPX document fur-
ther these relationships (Additional file 1).
A simple logistic model using S-HPX as an independ-
ent variable was used to determine the cutoff values of 
S-HPX for separation of the healthy, fibrotic, and cir-
rhotic participants in the discovery set. The resulting 
model performs well with AuROCs of 0.77 and 0.90 in 
separating patients who developed fibrosis from the con-
trols and cirrhotic from the fibrotic patients, respectively 
(Fig.  4a). When the S-HPX cut-off between the fibrotic 
and control groups was set at 13.5, sensitivity is 91 % and 
specificity is 52  %. With the cut-off point 42.5 between 
cirrhotic and fibrotic patient, sensitivity is 96 % and spec-
ificity is 71 %.
The diagnostic performance of S-HPX was further 
tested using 45 verification samples using the LC–MS/
Fig. 3 Direct quantification of S-HPX at progressing stages of liver 
disease. Direct quantification of S-HPX in samples of the following 
groups of controls and HALT-C participants in the discovery sample 
set: a disease-free controls (n = 23), liver fibrosis (n = 22), and cirrho-
sis (n = 24) patients; b 23 healthy volunteers at four different blood 
draw times. The box and whisker plots represents median, 25th–75th 
percentile, range of values, and outliers; *significantly different at 
p < 0.01 from control and **from the fibrosis group
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MS-MRM measurement of S-HPX and cutoffs deter-
mined in the discovery set. The results show an AuROC 
0.82 (Fig.  4b) for the separation of fibrotic and disease-
free groups, which is better than the AuROC of 0.77 in 
the discovery set. Here we cannot compare S-HPX to 
other measures of fibrosis due to lack of other variables 
in controls. However, diagnostic performance of plate-
let count, AFP, and the FIB-4 and APRI indexes were 
compared with S-HPX in distinguishing the cirrhotic 
patients from the fibrotic patients. S-HPX achieves 
AuROC = 0.84 which is higher than any other measures 
with sensitivity and specificity of S-HPX being 60 and 
93 %, respectively (Table 4).
Discussion
Non-invasive methods including liver imaging, elastogra-
phy, and serologic monitoring increasingly complement 
liver biopsy in diagnosis of fibrotic changes associated 
with chronic liver diseases [5–9]. Ultrasound elastog-
raphy is perhaps the fastest developing non-invasive 
method [7] but glycosylation of liver secreted proteins 
is an attractive strategy for serologic monitoring of liver 
disease [13, 16, 17, 19–21]. N-glycosylation of proteins 
has been explored in detection of pre-malignant liver 
disease [16, 20] or HCC [17, 21, 39]. AFP-L3, the core-
fucosylated N-glycoform of AFP, is an established marker 
of HCC risk [39] and Debruyne et  al. [21] showed that 
alpha-1,3-fucosylated triantennary N-glycans associ-
ated with hemopexin increase in HCC compared to the 
disease-free, fibrotic, and cirrhotic patients. GlycoFi-
broTest measures increase in core fucosylated bisect-
ing N-glycans, detached enzymatically from proteins, to 
detect progressive stages of liver fibrosis [16]. A number 
of liver secreted glycoproteins have been shown to carry 
abnormal N-glycans, especially fucosylated glycans [17, 
36]. However, O-glycosylation of proteins has not been to 
our knowledge explored in connection with liver disease.
Our study examines, for the first time, site-specific 
O-glycoforms of HPX in liver disease (Table 2). We detect 
15 O-glycoforms and find that two major glycoforms, 
HexNAc-Gal-Neu5Ac and HexNAc-Gal-2Neu5Ac, rep-
resent approximately 85 % of the total. Additional minor 
O-glycoforms represent multiplication of the same struc-
tures attached to additional serine/threonine residues of 
the same tryptic peptide [26]. Contrary to the increased 
occupancy of the additional O-glycosites of HPX 
observed in congenital disorders of glycosylation [26], 
we do not observe changes in occupancy of additional 
sites in liver disease but observe increased sialylation of 
the O-glycan attached to the N-terminal threonine (T1) 
of HPX. It is important to note that the increase in sia-
lylation is specific to the O-glycans of HPX. We have 
examined N-glycopeptides in the tryptic digests of HPX 
simultaneously and do not observe increase in their sia-
lylation except for an approximately 30 % increase in case 
of one of the N-glycopeptides (Additional file 1). This is 
marginal compared to the several-fold increase in the 
di-sialylated O-glycoform of HPX observed in the same 
samples (Fig. 2).
We have therefore developed targeted LC–MS3 and 
LC–MS/MS-MRM assays for quantification of the di-sia-
lylated and mono-sialylated glycoforms [12] and we use 
the assays, adapted to the analysis on the 6500 QTRAP 
mass spectrometer, to determine S-HPX (ratio of the 
Table 3 Associations between clinical variables and S-HPX
Spearman correlation coefficients were evaluated in all samples combined and in the fibrosis and cirrhosis groups, separately
* Significance level <0.05
All (n = 46) Fibrosis (n = 22) Cirrhosis (n = 24)
rs p value rs p value rs p value
Age −0.034 0.832 0.160 0.489 0.017 0.945
Bilirubin (mg/dL) 0.409 0.008* 0.088 0.705 0.393 0.086
Creatinine (mg/dL) −0.166 0.270 0.129 0.568 −0.363 0.081
INR 0.390 0.012* 0.039 0.866 0.006 0.979
MELD 0.279 0.061 0.215 0.338 0.134 0.534
AFP (ng/mL) 0.578 <0.001* 0.429 0.052 0.439 0.053
Albumin (g/dL) −0.436 0.004* −0.040 0.862 −0.511 0.021*
Alk. phosphastase (U/L) 0.195 0.193 0.116 0.608 0.185 0.387
ALT (U/L) 0.337 0.031* −0.163 0.480 0.346 0.135
AST (U/L) 0.520 0.001* −0.087 0.709 0.747 0.001*
Platelet (109/L) −0.564 <0.001* −0.462 0.035* −0.358 0.121
FIB-4 0.612 <0.001* 0.366 0.103 0.574 0.008*
APRI 0.562 <0.001* 0.158 0.493 0.589 0.006*
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two glycoforms) in a pilot study of HALT-C participants. 
Analysis of the results using the two targeted methods 
shows that quantification of S-HPX by LC–MS/MS-MRM 
directly in serum has lower variability (RSD  =  6  % in 
repeated analysis of a QC sample) compared to the LC–
MS3 assays (RSD = 18 %) and has sufficient sensitivity on 
the 6500 QTRAP instrument to achieve quantification in 
all samples examined. We have therefore used the LC–
MS/MS-MRM assay for the final quantification of S-HPX.
Our results show that S-HPX increases progressively in 
fibrotic and cirrhotic participants compared to disease-
free controls (Fig.  3). The LC–MS/MS-MRM assay has 
adequate analytical performance for direct quantifica-
tion of S-HPX in serum samples which could facilitate its 
development into a reliable clinical test. The combined 
novelty of monitoring specific O-glycoforms of HPX by 
the newly optimized LC–MS/MS-MRM workflow makes 
our quantification of S-HPX in liver disease quite unique 
and efficient.
At this point, we do not know the mechanism responsi-
ble for the increase of S-HPX in liver disease; further stud-
ies will be needed to explore the formation and degradation 
of these sialylated O-glycoforms of HPX. While IFN treat-
ment seems to lower somewhat S-HPX in the HALT-C 
participants, this trend is not significant (Additional file 1) 
and does not decrease the ability of S-HPX to distinguish 
fibrotic and cirrhotic disease. IFN treatment, especially in 
patients achieving a sustained viral response, reduces risk 
of HCC [40] but maintenance treatment with pegylated IFN 
was not found effective in the HALT-C trial [41, 42]. Since 
Fig. 4 ROC curve analysis of progressing liver disease. ROC curves comparing the following groups based on measurement of S-HPX: a discovery: 
control (n = 23) versus fibrosis (n = 22) and fibrosis (n = 22) versus cirrhosis (n = 24); b validation: control (n = 15) versus fibrosis (n = 15) and 
fibrosis (n = 15) versus cirrhosis (n = 15)
Table 4 ROC models comparing influence of clinical variables determined at baseline visit on separation of the fibrosis 
and cirrhosis groups in the validation set
Samples were used in Fig. 4b
a Optimal cut-off point was calculated based on fitted models from the discovery set
Cut‑off pointa Sensitivity (%) Specificity (%) AuROC SE 95 % CI
AFP 11.6 50 79 0.65 0.153 (0.35, 0.95)
Platelet 163 80 50 0.63 0.134 (0.37, 0.89)
APRI 1.45 60 86 0.73 0.145 (0.44, 1.00)
FIB-4 2.60 80 71 0.74 0.144 (0.47, 1.00)
S-HPX 42.5 60 93 0.84 0.145 (0.53, 1.00)
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the IFN treatment is not expected to be clinically relevant, 
we did not further study its effect. To generate leads for fur-
ther exploration, we correlated the appearance of S-HPX 
with available demographic and clinical factors. These asso-
ciations show that S-HPX correlates with AFP, ALT, AST, 
INR and bilirubin and correlates negatively with albumin 
and platelet count (Table  3). AFP and platelet count are 
established measures of liver disease and HCC. Previous 
analyses of the HALT-C trial [43] and other populations 
[44] showed that serum AFP is elevated in patients with 
advanced chronic hepatitis C, with or without HCC, espe-
cially among female and African American patients [45]. 
Platelet count [46] and the APRI [47] or FIB-4 [48] indexes, 
which combine platelet count with AST and ALT, have been 
associated with the degree of fibrosis and disease severity in 
the HALT-C study. These factors appear to be regulated in 
a similar way as S-HPX; however, S-HPX performs compa-
rably well or better than any of these measures in our study. 
Further studies in larger population samples are required to 
establish definitive cut-offs of S-HPX and to validate diag-
nostic models in combination with other variables.
Conclusion
In conclusion, we have detected, for the first time, eleva-
tion of di-sialylated O-glycoform of HPX in liver disease 
and established LC–MS/MS-MRM assay for its quan-
tification in serum. We propose that this measure could 
serve as a simple indicator of liver fibrosis alone or in 
combination with other factors currently used to classify 
liver disease. Analysis of the sialylated glycoform at a spe-
cific site of HPX attachment directly in unfractionated 
serum facilitates clinical applicability of the robust MRM 
quantification method. The pathophysiological mecha-
nisms leading to increased S-HPX and definitive assess-
ment of its behavior in liver disease of HCV and other 
etiologies will require further studies.
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